Biosimilars In The Pharmacy

Thursday July 16, 2020

biosimilars in the pharmacy

Biosimilars in the pharmacy benefit employers driving appropriate use and transparency.

Despite the fact that less than 2 percent of the U.S. population uses biologic drugs, they account for 26 percent of national prescription drug spending. Biosimilars can expand options, enhance affordability, and increase access to therapy. It’s been estimated that biosimilars could save patients and the healthcare system from $54 to $250 billion over their first 10 years on the market without compromising outcomes.

The National Alliance of Healthcare Purchaser Coalitions outlines steps employers can take to benefit from the savings biosimilars offer.


About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accessiblemeds.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

 

GRx+Biosims 2020

Planning + Ready: Join us November 9-11, 2020 for the premier scientific and regulatory event for the U.S. generics and biosimilars industries.

LEARN MORE

Recent Tweets

If the entire Affordable Care Act (#ACA) is overturned as unconstitutional, it could eliminate the Biologics Price Competition and Innovation Act (#BPCIA) and threaten the accessibility of life-saving treatments in the U.S.

Read more: https://www.washingtonpost.com/opinions/letters-to-the-editor/striking-down-obamacare-would-also-nix-generic-biologic-drugs/2020/06/28/44a4a630-b7c4-11ea-9a1d-d3db1cbe07ce_story.html

Load More...

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER